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ABSTRACT 
Objective: The objective of the present study was to formulate flurbiprofen (FLB) emulgel, evaluation of the formulations and the selection of an 
optimized formulation through in vitro drug release and drug content studies. Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) 
requiring frequent administration and its chronic intake can lead to systemic side effects like gastric irritation and GI bleeding. The development of 
a dermal drug delivery system can overcome these side effects.  
Methods: The emulgel formulations were produced using different combinations of oil and emulsifying agents. Carbopol 940 was used as a gelling 
agent. The prepared emulgels were evaluated for general appearance, pH, spreadability, extrudability, drug content, in vitro drug release, average 
globule size and viscosity. 
Results: Optimized formulation F7 showed a better in vitro drug release compared to the marketed gel preparation. The stability study for the 
optimized formulation was carried out at 25 °C/60 % RH for 3 mo and the emulgel was found to be stable concerning the physical appearance, pH 
and drug content. 
Conclusion: The study revolved around the formulation of emulgel containing Flurbiprofen for dermal delivery of the drug. Emulgel was 
formulated with the purpose to enhance the permeation of poorly water-soluble drug FLB. The study concluded that the optimized emulgel 
containing FLB exhibited better in vitro drug release profile compared to the marketed formulation. 
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INTRODUCTION 
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are the category 
of drugs used for the long term treatment of Rheumatoid arthritis 
(RA) and osteoarthritis. When administered by oral route, these 
drugs cause systemic side effects like gastric ulceration and 
irritation but when administered as a dermal drug delivery 
system, the systemic side effects as well as the first-pass 
metabolism of the drug is bypassed thereby delivering the drug at 
a predetermined rate and improving patient compliance. 
Flurbiprofen, [2-(2-fluoro-4-biphenylyl) propionic acid] is a potent 
chiral non-steroidal anti-inflammatory agent with antipyretic and 
analgesic action and is approved by USFDA for the treatment of 
rheumatoid arthritis, osteoarthritis, and alkylosing spondylitis. It 
has a half-life of 4.7 h and needs frequent administration and its 
chronic intake could result in systemic side effects like gastric 
irritation and gastric bleeding [1-5]. 
Owing to the various disadvantages associated with semisolids like 
ointments, creams and lotions like stickiness, less spreading abilities 
and the need for the application of semisolids with rubbing and 
stability issues, transparent gels are more preferred in cosmetics as 
well as pharmaceutical preparations but the drawback of gels is the 
inability to incorporate and deliver hydrophobic drugs through the 
aqueous gel base. To overcome this disadvantage, a novel emulgel 
approach could be used to incorporate the hydrophobic drug into 
the aqueous gel base. Emulgels are either oil in water or water in oil 
emulsions gelled by mixing with a gelling agent and combine the 
properties of both gel and emulsions thereby acting as a dual control 
release systems [6-7]. 
The purpose of this novel work was to formulate flurbiprofen 
emulgel, providing therapeutic effect at the localized site and 
eliminating gastrointestinal side effects associated with the oral 
formulations. The emulgel was formulated using Carbomer 940 
as a polymer. The effect of varying concentration of emulsifying 
agents and oil phase on the drug release was investigated. 
MATERIALS AND METHODS 
Flurbiprofen was obtained as a gift sample from FDC-Ltd (Roha 
Maharashtra), carbopol 940 was obtained from lubrizol, tween 80, 
span 80 and triethanolamine were obtained from molychem, liquid 
paraffin was obtained from SD-chemicals and fines ltd. All the 
solvents were of analytical grade. 
Preparation of an emulgel 
The composition of an emulgel is as shown in table I.  
Preparation of Carbopol 940 gel base 
Carbopol 940 was soaked in a sufficient quantity of distilled water 
for 3 h and then pH was adjusted to 6.5 using triethanolamine to 
yield the gel.  
Preparation of an emulsion 
Preparation of oil phase: Oil phase of the emulsion was prepared by 
dissolving Span 80 in light liquid paraffin followed by dispersing the 
drug in it since Flurbiprofen is hydrophobic by nature.  
Preparation of an aqueous phase: The aqueous phase was prepared 
by dissolving Tween 80 in purified water. Methylparaben was then 
dissolved in a sufficient quantity of ethanol and propylene glycol and 
added to the aqueous phase. Both the oily and aqueous phases were 
separately heated to 70-80˚C, then the oily phase was added to the 
aqueous phase with continuous stirring followed by cooling to room 
temperature to yield an o/w emulsion.  
Preparation of an emulgel 
The final emulgel was formed by the addition of the emulsion to 
Carbopol gel in the ratio of 1:1 with constant stirring [8]. 
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Table 1: Composition of different formulation batches (% w/w) 
Formula F1 F2 F3 F4 F5 F6 F7 F8 F9 
Flurbiprofen  1 1 1 1 1 1 1 1 1 
Carbopol 940  1 1 1 1 1 1 1 1 1 
Liquid paraffin  5 5 5 7.5 7.5 7.5 10 10 10 
Span 80  0.9 1.9 2.8 0.9 1.9 2.8 0.9 1.9 2.8 
Tween 80 1.1 2.1 3.2 1.1 2.1 3.2 1.1 2.1 3.2 
Propylene glycol 5 5 5 5 5 5 5 5 5 
Ethanol  2 2 2 2 2 2 2 2 2 
Methyl Paraben 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
Purified water qs to 100 ml 
Triethanolamine qs to adjust pH to 6 to 7 
 
Drug-polymer compatibility study 
The drug-polymer compatibility study was carried out using FTIR 
spectrophotometer (Schimadzu). The IR spectra of the drug as well 
as the physical mixture of the drug and polymer in the ratio of 1:1 
were recorded. All the spectras were recorded in the range of 400-
4000 cm-1 [8]. 
Characterization of the formulated emulgel 
General appearance 
The prepared emulgel formulations were visually inspected for color 
and appearance since no quantitative estimation could be done on 
this parameter due to the non-availability of the required facility. 
 
 
Fig. 2: Formulated emulgels 
 
pH 
The pH of the skin is normally between 6 to 7, and it is therefore 
desirable that the preparation used for topical application does not 
fall beyond this value or else it will cause severe irritation to the 
skin. The pH of all the formulations was evaluated using a pH meter 
and the pH was measured at room temperature [8]. 
Spreadability 
To study the spreadability of formulations, a special apparatus was 
designed. Spreadability was expressed in terms of time in seconds 
taken by two slides to slip off from formulations placed between, 
under the application of a certain load. Lesser the time taken to 
separate the two slides, better is the spreadability. Two glass slides 
of 6×2 cm each were selected. The formulation was placed over one 
of the slides. This slide was placed on another slide in such a way 
that the formulation was sandwiched between the two slides. The 
formulation between the two slides was squeezed consistently to 
frame a slight layer; for this reason, weight 100 g was placed on the 
upper slide. The excess of the formulation adhering to the slide was 
scrapped off after the weight was removed. The lower slide was 
fixed on the surface of the apparatus and the upper slide was tied to 
the string. To this string, 20 g load was applied with the help of a 
simple pulley. Under the direction of weight applied, the time taken 
for the upper slide to move the distance i.e. of 6 cm and separate 
away from the other slide (lower) was noted. The experiment was 
repeated three times and the average of such determination was 
calculated for each formulation by using the formula [9, 10]: 
S =  M × L/T 
Where, S = spreadability,  
M = weight tied to the upper slide,  
L = length of glass slides  
T = time taken to separate the slides completely from each other 
Extrudability 
Test to measure the force required to expel the material from the 
tube. The formulation whose extrudability was to be checked was 
filled in a clean, lacquered aluminium collapsible metal tube. 
Extrudability of the emulgel was the weight required to extrude 
from a lacquered aluminum collapsible tube at least 0.5 cm ribbon of 
emulgel in 10 s on the application of weight in grams. More the 
quantity extruded better is the extrudability. The measurement of 
the extrudability of each formulation was determined in triplicate 
and the average values are presented. The extrudability is than 
calculated by using the following formula [11]: 
Extrudability = Applied weight to extrude emulgel from tube (in g)
/Area (in cm²) 
Drug content 
Gel formulation (1 gram) was dissolved in methanol. The solution 
was filtered to obtain a clear solution. The absorbance of the 
resulting solution was measured using a UV Visible 
spectrophotometer after suitable dilution to determine the drug 
content [12]. 
In vitro drug release 
In vitro release studies were done using diffusion studies. In vitro 
drug release behavior of the drug from the emulgel formulations 
was investigated using the dialysis membrane. Dialysis membrane 
previously soaked in the phosphate buffer pH 7.4 was used as the 
permeation membrane. 50 ml of Phosphate buffer pH 7.4 was placed 
in a beaker (receptor compartment). An accurately weighed quantity 
(1 g) of the formulated emulgel was then uniformly spread on the 
dialysis membrane (donor compartment) and this membrane was 
tied to the diffusion tube (a hollow tube open on both sides). One 
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side of the dialysis membrane was kept in contact with the medium 
phosphate buffer pH 7.4. The medium was constantly agitated using 
a magnetic stirrer and the temperature was maintained at a constant 
of 37±1 °C throughout the operation. Samples of 5 ml volume were 
then withdrawn from the receptor compartment at intervals of 1 
hour for 8 h and the amount withdrawn was replaced with a fresh 
volume of the medium. The samples withdrawn were then analyzed 
for the amount of Flurbiprofen released by UV spectrophotometric 
method by measuring the absorbance of the samples at 247 nm 
against Phosphate Buffer pH 7.4 taken as blank [8]. 
 
Table 2: Details of in vitro release studies 
Diffusion medium pH 7.4 Phosphate buffer 
Volume of diffusion medium used 50 ml 
Temperature 37 °C±1 °C 
Time interval for sampling 1 h 
Speed 50 rpm 
Volume of sample withdrawn 5 ml 
Detection wavelength 247 nm 
 
Average globule size 
The average globule size was measured by a light microscope at 40X 
magnification [8]. 
Viscosity 
The viscosity of the optimized emulgel formulations is determined 
by Brookfield Viscometer using spindle no. 64 at 10 rpm [5]. 
Stability study 
Stability study was performed on the optimized formulation F7. The 
preparation was packed in an aluminum collapsible tube (5g) and 
was subjected to stability studies as 25 °C/60 % RH for 3 mo. 
Thereafter the samples were withdrawn and evaluated for physical 
appearance, rheological properties, and drug content. All the test 
results were found to be in limits. Hence the formulations were 
stable understated storage conditions [6, 13, 16]. 
RESULTS 
Drug-polymer compatibility study 
The FTIR spectra of the pure Flurbiprofen and 1:1 mixture of 
Flurbiprofen and carbopol 940P is shown in fig. 2 and fig. 4, 
respectively. There was no change in the position or disappearance of 
any characteristic peak of Flurbiprofen, indicating the compatibility 
between the drug Flurbiprofen and polymer carbopol 940. 
 
 
Fig. 2: FTIR spectra of flurbiprofen 
 
 
Fig. 3: FTIR spectra of 1:1 mixture of flurbiprofen and carbopol 940 
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All formulation batches were found to be homogenous yellowish 
milky emulsions while emulgels were found to be yellowish-white 
viscous, creamy preparations. 
pH 
The pH of all the formulations was found to be as in table 3 follows 
Spreadability 
The spreadability of all the formulations ranged as follows, as in 
table 4. Formulation F7 was found to possess the highest 
spreadability. 
Drug content 
%. Drug content of all the formulations is as follows in table 5. 
 
Table 3: pH of formulations F1-F9 










*Data are represented as mean±standard deviation (SD), n=3 
 
Table 4: Spreadability of formulations F1-F9 











Table 5: Drug content of formulations F1-F9 










*Data are represented as mean±standard deviation (SD), n=3 
 
Table 6: Average droplet size range for formulations F1-F9 










*Data are represented as mean±standard deviation (SD), n=3 
 
Average droplet size 
The average droplet size measurements are as shown in the 
table 6. 
In vitro drug release 
The In vitro drug release of all the formulations F1-F9 and marketed 
gel formulation ranged as follows. 
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Table 7: In vitro drug release of formulations F1-F9 and marketed gel formulation 
Time (h) % Cumulative drug release (%CDR) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 Marketed gel formulation 
0 0 0 0 0 0 0 0 0 0 0 
1 19.77 15.39 13.53 17.32 22.16 13.51 26.59 22.00 20.59 6.73 
2 30.14 29.68 21.74 29.30 32.16 23.88 42.71 40.42 38.71 10.73 
3 41.41 37.44 35.25 45.44 43.14 30.99 57.40 55.98 50.40 15.20 
4 44.52 42.08 39.76 53.90 51.57 34.84 68.72 65.47 62.88 23.54 
5 51.30 48.48 42.90 60.44 56.57 40.31 79.59 78.28 70.90 26.22 
6 58.98 55.25 52.88 63.54 60.11 50.31 88.42 83.09 81.44 30.32 
7 64.74 63.67 58.96 69.88 66.39 57.06 97.97 93.80 90.54 34.17 
8 69.23 66.91 63.26 74.10 71.59 62.90 99.00 95.18 92.67 38.90 
 
Table 8: Values of the regression coefficient (R2) and release kinetics of formulation in phosphate buffer pH 7.4 
Code Zero-order First-order Peppas Higuchi 
R2 K R2 K R2 K R2 n 
F1 0.9485 7.99 0.9672 0.287 0.994 0.59 0.994 27.03 
F2 0.9599 7.91 0.9416 0.323 0.985 0.68 0.991 27.60 
F3 0.9712 7.65 0.9540 0.357 0.987 0.75 0.987 27.54 
F4 0.9341 8.96 0.9160 0.331 0.977 0.70 0.983 31.42 
F5 0.9278 8.13 0.890 0.0668 0.994 0.56 0.994 26.97 
F6 0.9815 7.40 0.974 0.346 0.991 0.71 0.977 26.51 
F7 0.967 10.56 0.956 0.310 0.995 0.65 0.994 41.75 
F8 0.955 10.39 0.930 0.335 0.985 0.70 0.991 41.30 
F9 0.970 10.23 0.943 0.343 0.991 0.72 0.996 40.66 
 
Table 9: The extrudability values of formulations F1-F9 










*Data are represented as mean±standard deviation (SD), n=3 
 
Table 10: Results of the stability study (mean±SD, n=3) 
Before After 
Appearance *pH *Drug content (%) Appearance *pH *Drug content (%) 
White, creamy, viscous 6.7±0.53 100±1.53 White, creamy, viscous 6.6±0.73 98±1.00 
 
Extrudability 
The extrudability values of formulations F1-F9 were found to be as 
per table 9. 
Viscosity 
Viscosity measurement was performed on the optimized 
formulation (F7) and was found to be 36300 cPs. 
Stability studies 
The results of the stability studies are as follows in table 10. 
DISCUSSION 
FTIR was performed to detect any sign of interaction, which would 
be reflected by a change in the position or disappearance of any 
characteristic peak of Flurbiprofen. IR scans of pure drug 
flurbiprofen and 1:1 physical mixtures of flurbiprofen and carbopol 
940 were taken. From the IR spectras shown in fig. 2 and fig. 3, it 
was observed that there was no interaction of the drug with any of 
the excipients. The appearance of the formulations was found to be 
satisfactory. The pH of all the formulations was found to be neutral 
and was close to the pH of the skin and hence it should not cause any 
irritation to the skin [14]. 
The spreadability of all the formulations was satisfactory. The 
highest spreadability was shown by optimized formulation F7 ie 
7.97 cm. Drug content was almost uniform in all the formulations 
and was found to be between 97.9 to 100.8 %. The results of the 
average globule size indicate the globule size of droplets varied from 
11.5 to 17.5 μm. The in vitro release of the drug from the formulated 
emulgels was found to be higher as compared to the marketed 
Brufen gel. Optimized formulation F7 showed a release of 99%, 
whereas the marketed formulation showed a release of 38.90% 
indicating that the formulated emulgel had better release compared 
to the marketed product. The release of the drug from the emulgel 
formulations could be ranked in the descending order as follows: 
F7>F8>F9>F4>F5>F6>F1>F2>F3 
The release was found to vary according to the concentration of liquid 
paraffin, span 80 and tween 80. When the concentration of emulsifier’s 
i. e span 80 and tween 80 was less; the release exhibited was more.  
The in vitro release data was fitted to the curve kinetic models to 
know the mechanism of drug release. Regression coefficient (R2) 
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values for zero-order ranged from 0.927-0.981 and for first-order 
plots ranged from 0.890-0.974. R2values were found to be higher for 
zero-order than for first-order. According to the regression 
coefficients tabulated in table 8 for all the formulations, it is evident 
that all the formulations follow zero-order drug release kinetics. 
Since regression coefficients of higuchi plot were found to be close 
to 1 according to the above-tabulated data, it also reveals that all the 
formulations exhibit diffusion drug release mechanism. In the case 
of Korsemeyer peppas plot ‘ n ‘ values were more than 0.5, which 
indicates non-fickian drug release kinetics. Hence, from the data 
obtained from all the models, it was concluded that the drug release 
through the flurbiprofen emulgel formulations is diffusion-
controlled following zero-order kinetics with non-fickian diffusion 
pattern [11, 18]. 
The viscosity of the optimized formulation was found to be 
satisfactory. 
The results of the stability studies indicated that the optimized 
emulgel was found to be stable concerning to physical appearance, 
pH and drug content at 25 °C/60 % RH for a period of 3 mo. 
CONCLUSION 
The present study deals with the formulation development and 
optimization of flurbiprofen emulgel. The optimization was done 
based upon the drug content and in vitro drug release. The kinetic 
modeling revealed that Flurbiprofen was a good fit to the zero-order 
and Higuchi model. The emulgel was found to exhibit diffusion 
controlled drug release according to Higuchi model. Overall the 
release from the emulgel was zero-order, non-fickian drug release. 
Formulation batch F7 showed better drug release compared to the 
marketed gel (Brufen) formulation thus revealing the better results 
of the formulated emulgel. Thus the successful attempt of emulgel 
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